Home » Technology News » 2011 » August » August 12, 2011

Engineered dual-action protein prevents cancer cells from creating blood vessels better

August 12, 2011 - Washington

Researchers at Stanford University have developed a new type of dual-action Protein that significantly prevent cancer cells from creating blood vessels, choking off their much-needed blood and nutrient supply to halt the growth of tumours.

The engineered Protein blocks not one, but two of the chemical receptors that control the creation of new capillaries - a process known as angiogenesis.

When delivered in a nutrient-rich matrix and implanted in mice, the Stanford Protein showed dramatic ability to halt the creation of new capillaries.

"Samples treated with our dual-action Protein have minimal blood vessel formation, similar to a sample in which angiogenic factors are absent," said lead researcher Jennifer Cochran, PhD, assistant professor of bioengineering.

"Importantly, this engineered Protein more strongly inhibits angiogenic processes compared to single-receptor blockers," she added.

Beyond cancer, Cochran noted, the prevention of angiogenesis could prove helpful in the treatment of diseases such as macular degeneration, one form of which can lead to visual impairment or even blindness when unchecked capillaries grow in the retina.

The discovery has been published online Aug. 8 in the Proceedings of the National Academy of Sciences.


Comment on this story